Benefit Agmatine Effects in Experimental Multiple Sclerosis. CNS Nitrosative and Oxidative Stress Suppression / Protektivni Efekti Agmatina U Eksperimentalnoj Multiploj Sklerozi. Supresija Nitrozativnog I Oksidativnog Stresa U CNS-U

Open access

Summary

The aim of this study was to investigate the exogenous agmatine influence on nitrosative and oxidative stress parameters in acute phase of multiple sclerosis (MS) experimental model, experimental autoimmune encephalomyelitis (EAE).

EAE was induced by subcutaneous injection of myelin basic protein (50 μg per animal). Sprague-Dawley rats were divided into five groups: I group - (CG), treated by PBS (i.p.), II group - (EAE), III group - (CFA), treated with Complete Freund’s adjuvant (0.2 ml subcutaneously), IV group - (EAE+AGM), treated by agmatine (75 mg/kg bw i.p.) upon EAE induction and V group - (AGM), received only agmatine in the same dose. The animals were treated every day during experiment - from day 0 to 15, and clinically scored every day. They were sacrificed on day 16 from MBP application. NO2+NO3, S-nitrosothiols (RSNO), malondyaldehide (MDA) and reduced glutathione (GSH) concentrations and superoxide dismutase (SOD) activity were determined in rat whole encephalitic mass (WEM) and cerebellum homogenates.

Agmatine exerted strong protective effects on EAE clinical symptoms (p<0.05). In EAE brain homogenates, NO2+NO3, RSNO and MDA concentrations were increased compared to CG values. Agmatine treatment diminished NO2+NO3, RSNO and MDA levels in EAE animals (p<0.05). In EAE rats, GSH level and SOD activity were decreased compared to CG values, but agmatine treatment increased both parameters compared to EAE untreated animals (p<0.05). Immunohistochemical staining supported the clinical and biochemical findings in all groups.

The CNS changes in EAE are successfully supressed by agmatine application, which could be the the new aspect of the neuroprotective effects of agmatine.

1. Li G, Regunathan S, Barrow CJ et al. Agmatine: an endogenous clonidine-displasing substance in the brain. Science 1994; 263: 966-9. http://dx.doi.org/10.1126/science.7906055

2. Halaris A, Plietz J. Agmatine metabolic pathway and spectrum of activity in brain. CNS drugs 2007; 21: 885-900. http://dx.doi.org/10.2165/00023210-200721110-00002

3. Hong S, Lee JE, Kim CY et al. Agmatine protects cultured retinal ganglial cells from tumor necrosis factoralpha - induced apoptosis. Life Sci 2009; 84: 28-32. http://dx.doi.org/10.1016/j.lfs.2008.10.006

4. Goracke-Postle CJ, Nguyen HO, Stone LS et al. Release of tritiated agmatine from spinal synaptosomes. Neuroreport 2006; 17: 13-7. http://dx.doi.org/10.1097/01.wnr.0000192739.38653.aa

5. Piletz JE, Chikkala DN, Ernsberger P. Comparison of the properties of agmatine and endogenous clonidinedisplacing substance at imidazoline and alpha-2 adrenergic receptors. J Pharmacol Exp Ther 1995; 272: 581-7.

6. Yang XC, Reis DJ. Agmatine selectively blocks the NMDA subclass of glutamate receptor channels in cultured mouse hippocampal neurons. J Pharmacol Exp Ther 1999; 288: 544-9.

7. Feng Y, Piletz JE, Leblanc MH. Agmatine suppresses nitric oxide production and attenuates hypoxic-ischemic brain injury neonatal rats. Pediatr Res 2002; 52: 606-11. http://dx.doi.org/10.1203/00006450-200210000-00023

8. Olmos G, DeGregorio-Rocasolano N, Paz Regalado M et al. Protection by imidazol(ine) drugs and agmatine of glutamate- induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. Br J Pharmacol 1999; 127: 1317-26. http://dx.doi.org/10.1038/sj.bjp.0702679

9. Wekerle H, Kojima K, Lannes-Vieira J et al. Animal models. Ann Neurol 1994; 36: 547-53. http://dx.doi.org/10.1002/ana.410360714

10. Steinman L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 1999; 24: 511-4. http://dx.doi.org/10.1016/S0896-6273(00)81107-1

11. Wekerle H. T-cell autoimmunity in the central nervous system. Intervirology 1993;35:95-100.

12. Mdel MP, Monson ML. Potential role of humoral immunity in the pathogenesis of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Front Biosci 2007; 12: 2735-49. http://dx.doi.org/10.2741/2268

13. Beckman JS, Koppenol WH. Nitric oxide, superoxide and peroxynitrite: the good, bad and ugly. Am J Physiol 1996; 271: C1424-37.

14. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls and controls. Cell 1994;78: 915-8. http://dx.doi.org/10.1016/0092-8674(94)90266-6

15. Jourd’heuil D, Gray L, Grisham MB. S-nitrosothiol formation in blood of lipopoolysaccharide-treated rats. Biochem Biophys Res Commun 2000; 273: 22-6. http://dx.doi.org/10.1006/bbrc.2000.2892

16. Marozkina NV, Gaston B. S-Nitrosylation signaling regulates cellular protein interactions. Biochim Biophys Acta 2011; 1820(6): 722-9. http://dx.doi.org/10.1016/j.bbagen.2011.06.017

17. Nozik-Grayck E, Suliman HB, Piantadosi CA. Extracellular superoxide dismutase. Int J Biochem Cell Biol 2005; 37(12): 2466-71. http://dx.doi.org/10.1016/j.biocel.2005.06.012

18. Paintlia AS, Pantlia MK, Khan M et al. HMG-KoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J 2005; 19: 1407-21. http://dx.doi.org/10.1096/fj.05-3861com

19. Prasad R, Giri S, Nath N et al. 5-aminoimidazole-4- carboxamide-1-beta-4-ribofuranoside attenuates experimental autoimmune ecephalomyelitis via modulation of endothelial-monocyte interaction. J Neurosci Res 2006; 84: 614-25. http://dx.doi.org/10.1002/jnr.20953

20. Tao F, Lu SD, Huang YL et al. Role of excitatory amino acid transporter 1 in neonatal rat neuronal damage induced by hypoxia-ischemia. Neuroscience 2001; 102 (3): 503-13. http://dx.doi.org/10.1016/S0306-4522(00)00485-1

21. Khan M, Sekhon B, Giri S et al. S-Nitrosoglutathione reduces inflammation and protects brain against focal cerebral ischemia in a rat model of experimental stroke. J Cereb Blood Flow Metab 2005; 25(2): 177-92. http://dx.doi.org/10.1038/sj.jcbfm.9600012

22. Dalmau I, Vela JM, González B et al. Dynamics of microglia in the developing rat brain. J Comp Neurol 2003; 458(2): 144-57. http://dx.doi.org/10.1002/cne.10572

23. Gosselin RD, Gibney S, O'Malley D et al. Region specific decrease in glial fibrillary acidic protein immunoreactivity in the brain of a rat model of depression. Neuroscience 2009; 159(2): 915-25. http://dx.doi.org/10.1016/j.neuroscience.2008.10.018

24. Navaro-Gonzalvez JA, Garcia-Benayas, C, Arenas J. Semiautomated measurement of nitrate in biological fluids. Clin Chem 1998; 44: 679-81.

25. Minamiyama Y, Takamura S. Effect of thiol status on nitric oxide metabolism in the circulation. Arch Biochem Biophys 1997; 341(1): 186-92. http://dx.doi.org/10.1006/abbi.1997.9956

26. Giustarini D, Milzani A, Dalle-Donne I et al. Detection of S-nitrosothiols in biological fluids: a comparison among the most widely applied methodologies. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 851(1-2): 124-39. http://dx.doi.org/10.1016/j.jchromb.2006.09.031

27. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxidation in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-8. http://dx.doi.org/10.1016/0003-2697(79)90738-3

28. Sedlak J, Lindsday R. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 1968; 25: 192-205. http://dx.doi.org/10.1016/0003-2697(68)90092-4

29. Minami M, Yoshikawa H. A simplified assay method of superoxide dismutase activity for clinical use. Clin Chim Acta 1979; 92: 337-42. http://dx.doi.org/10.1016/0009-8981(79)90211-0

30. Lowry OH, Rosebrough NJ, Farr AL et al. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-75.

31. Zielasek J, Jung S, Künzig H et al. Administration of nitric oxide inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis. J Neuroimmunol 1995; 95: 81-8. http://dx.doi.org/10.1016/0165-5728(94)00192-Q

32. Encinas JM, Manganas L, Enikolopov G. Nitric oxide and multiple sclerosis. Curr Neurol Neurosci Rep 2005; 5(3): 232-8. http://dx.doi.org/10.1007/s11910-005-0051-y

33. Danilov AI, Andersson M, Bavand N et al. Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis. J Neuroimmunol 2003; 136: 112-8. http://dx.doi.org/10.1016/S0165-5728(02)00464-2

34. Rejdak K, Eikelenboom MJ, Petzold A et al. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 2004; 63(8): 1439-45. http://dx.doi.org/10.1212/01.WNL.0000142043.32578.5D

35. Sabens Liedhegner EA, Gao XH, Mieyal JJ. Mechanisms of Altered Redox Regulation in Neurodegenerative Diseases-Focus on S-Glutathionylation. Antioxidants & Redox Signal 2012; 16(6): 543-66. http://dx.doi.org/10.1089/ars.2011.4119

36. Fabian RH, Rea RC. Neuronal toxicity by macrophages in mixed brain cell culture is augmented by antineuronal IgG and dependent upon nitric oxide synthesis. J Neuroimmunol 1993; 44: 95-102. http://dx.doi.org/10.1016/0165-5728(93)90272-Z

37. Redford EJ, Kapoor R, Smith KJ. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997; 120: 2149-57. http://dx.doi.org/10.1093/brain/120.12.2149

38. Jaffrey SR, Erdjument-Bromage,H, Ferris CD et al. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nature Cell Biol 2001; 3: 193-7. http://dx.doi.org/10.1038/35055104

39. Galea E, Regunathan S, Eliopoulos V et al. Inhibition of mammalian nitric oxide synthase by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J 1996; 316: 247-9.

40. Satriano J, Schwartz D, Ishizuka S et al. Suppression of inducible nitric oxide generation by agmatine aldehyde: beneficial effects in sepsis. J Cell Physiol 2001; 188 (3): 313-20. http://dx.doi.org/10.1002/jcp.1119

41. Regunathan S, Piletz JE. Regulation of inducible nitric oxide synthase and agmatine synthesis in macrophages and astrocytes. Ann NY Acad Sci 2003; 1009: 20-9. http://dx.doi.org/10.1196/annals.1304.002

42. Foster MW, McMahon TJ, Stamler JS. S-nitrosylation in health and disease. Trends Mol Med 2003; 9: 160-8. http://dx.doi.org/10.1016/S1471-4914(03)00028-5

43. Chung KK. Say NO to neurodegeneration. Role of Snitrosylation in neurodegenerative disorders. Neurosignals 2007; 15: 307-13. http://dx.doi.org/10.1159/000109071

44. Bizzozero O, DeJesus G, Bixler HA. Evidence of nitrosative damage in the brain white matter of patients with multiple sclerosis. Neurochem Res 2005; 30(1): 139-49. http://dx.doi.org/10.1007/s11064-004-9695-2

45. He J, Wang T, Wang P et al. A novel mechanism underlying the susceptibility of neuronal cells to nitric oxide: the occurrence and regulation of protein S-nitrosylation is the checkpoint. J Neurochem 2007; 102: 1863-74. http://dx.doi.org/10.1111/j.1471-4159.2007.04651.x

46. Motterlini R, Foresti R, Bassi R et al., Endothelial heme oxygenase-1 induction by hypoxia. Modulation by inducible nitric oxide synthase and S-nitrosothiols. J Biol Chem 2000; 275: 13613-20. http://dx.doi.org/10.1074/jbc.275.18.13613

47. Thorburne SK, Juurlink BH. Low glutathione and high iron govern the susceptability of oligodendroglial precursors to oxidative stress. J Neurochem 1996; 67: 1014-22. http://dx.doi.org/10.1046/j.1471-4159.1996.67031014.x

48. Calabrese V, Bella R, Testa D. Increased cerebrospinal fluid and plasma levels of ultraweak chemiluminiscence are associated with changes in the thiol pool and lipid soluble fluorescence in multiple sclerosis: the pathogenic role of oxidative stress. Drugs Exp Clin Res 1998; 24: 125-31.

49. Chi L, Ke Y. Depletion of reduced glutathione enhances motor neuron degeneration in vitro and in vivo. Neuroscience 2007; 144(3): 991-1003. http://dx.doi.org/10.1016/j.neuroscience.2006.09.064

50. Ruuls SR, Bauer J, Sontrop K, Huitinga I et al. Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 1995; 56(2): 207-17. http://dx.doi.org/10.1016/0165-5728(94)00154-G

51. van der Goes A, Brouwer J, Hoekstra K et al. Reactive oxygen species are required for the phagocytosis of myelin by macrophages. J Neuroimmunol 1999; 101 (1): 61-7. http://dx.doi.org/10.1016/S0165-5728(99)00133-2

52. Qi X, Guy J. Increase of manganese superoxide dismutase, but not of Cu/Zn-SOD, in experimental optic neuritis. Invest Ophthalmol Vis Sci 1997; 38(6): 1203-12.

Acta Facultatis Medicae Naissensis

The Journal of Faculty of Medicine in Nis

Journal Information


Cite Score 2017: 0.27

SCImago Journal Rank (SJR) 2017: 0.140
Source Normalized Impact per Paper (SNIP) 2017: 0.240

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 424 384 42
PDF Downloads 101 96 14